Navigation Links
Jennerex Announces First Patient Treated in Phase 2 Clinical Trial of Intravenous Delivery JX-594 In Patients with Advanced Liver Cancer
Date:7/25/2012

SAN FRANCISCO, July 25, 2012 /PRNewswire/ -- Jennerex, Inc., a private, clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic immunotherapies, today announced that the first patient has been treated in a Phase 2 clinical trial of intravenous treatment with JX-594 for patients with advanced hepatocellular carcinoma (HCC), or liver cancer, who have not received treatment with sorafenib—the current standard of care for this patient population.  This trial expands the development of the JX-594 program in HCC, which is currently being evaluated in a multi-national Phase 2b trial (TRAVERSE) in patients with advanced HCC who have failed prior sorafenib.

This Phase 2 trial is a multinational, single-arm, open-label study of JX-594 administered weekly by intravenous infusions in sorafenib-naive patients with advanced HCC. The primary objective of the study is to determine the radiographic response rate based on modified RECIST and modified Choi criteria.  Patients will subsequently be followed for progression-free survival and overall survival. The trial is being conducted at sites in South Korea, the United States, and Europe.  For more information about this trial as well as the Phase 2b TRAVERSE trial, please visit www.clinicaltrials.gov.

"We are pleased to have treated our first patient in this study, which will build on our experience with intravenous treatment with JX-594 and will allow us to assess anti-tumor activity of multiple intravenous infusions in the liver cancer patients specifically," said David H. Kirn, M.D., founder, chief medical officer and president of research and development.  "Unlike other treatments in the class, JX-594 can be administered intravenously, and we've shown that it has the ability to target tumors systemically—in addition to locally—and, therefore, has the
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Jennerex Appoints Dr. Laurent Fischer as President and Chief Executive Officer
2. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
3. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
4. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
5. Misonix Announces New Distribution Agreement For Panama
6. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
7. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
8. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
9. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
10. Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors
11. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... May 23, 2013  The need to add ... continuum was highlighted prominently at the 108 th ... (AUA), in San Diego.  According to SonaCare Medical, ... ultrasound (HIFU) technology, the need for image-guided technologies ... urologists to consider minimally invasive ablative treatments, was ...
(Date:5/23/2013)...  Every day, their baby stopped breathing, his collapsed bronchus ... April and Bryan Gionfriddo watched helplessly, just ... "Quite a few doctors said he had a good chance ... Gionfriddo , about her now 20-month-old son, Kaiba. "At ... would take it and run with it." They ...
(Date:5/23/2013)... 2013  Hologic, Inc. (Hologic or the Company) ... manufacturer and supplier of premium diagnostics, medical imaging ... serving the healthcare needs of women, today announced ... U.S. clinical practice comparing breast cancer screening with ... 2D mammography alone showed a significant reduction in ...
Breaking Medicine Technology:Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 2Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 3Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 4Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 5Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 6Baby's life saved with groundbreaking 3D printed device from U-M that restored his breathing 2Baby's life saved with groundbreaking 3D printed device from U-M that restored his breathing 3Baby's life saved with groundbreaking 3D printed device from U-M that restored his breathing 4First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 2First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 3First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 4
(Date:5/23/2013)... Internationally recognized as one of the top developmental ... years, Coach Nick Saviano’s proven methodology has ... Slam winners, World #1’s; Junior Wimbledon, US Open, French ... Champions, 8 Foreign National Junior Champions and more than ... and Eddie Herr winners - and boasts a 100% ...
(Date:5/23/2013)... 2013 Orange County film studio and visual ... light leaks for Apple's Final Cut Pro X ... you no longer have to worry about matching up the ... shot," Said Christina Austin, CEO of Pixel Film Studios, "You ... natural look." , ProLeak from Pixel Film Studios allows users ...
(Date:5/23/2013)... 2013 Today, Zane Benefits, Inc. published ... Zane Benefits, which provides comprehensive and flexible alternatives to ... defined contribution plans and health reimbursement ... question from employees is “does my employer have to ... necessarily. The health care reform law, called the Affordable ...
(Date:5/23/2013)... Reporter , , THURSDAY, May 23 (HealthDay News) -- Glucosamine ... hip and knee osteoarthritis may have an unexpected side ... small new study of older adults suggests. ... pressure (IOP) or pressure inside the eye. Left untreated, ... In the new study of 17 ...
(Date:5/23/2013)... Science published an article about bexarotene as ... important starting point for further Alzheimer,s research. The research ... VIB and KU Leuven in collaboration with the ... scientists at Janssen Pharmaceutica, Beerse, also tested this candidate ... were different, as were those of two American study ...
Breaking Medicine News(10 mins):Health News:Internationally Respected Tennis Coach, Nick Saviano Opens Summer Training Registration 2Health News:Pixel Film Studios Releases ProLeak Light Leaks for Final Cut Pro X Today 2Health News:Zane Benefits Publishes New Information on the Employer Mandate 2Health News:Zane Benefits Publishes New Information on the Employer Mandate 3Health News:Glucosamine Supplements Tied to Risk of Eye Condition 2Health News:Glucosamine Supplements Tied to Risk of Eye Condition 3Health News:New insights contradict promising Alzheimer's research 2
... more difficult to recognize and treat epilepsy in old ... Deutsches rzteblatt International ( Dtsch Arztebl Int ... Epilepsy Center of Johannes Gutenberg University in Mainz, Germany, ... therapeutic options. , It is often not possible ...
... Pharmaceuticals, Inc. (Nasdaq: TSPT ), a specialty ... proprietary products that address important therapeutic needs in the ... for its fourth quarter 2008 on Monday, March 23, ... the results will begin at 5:00 p.m. ET (2:00 ...
... benefit from tonal training , , FRIDAY, March 13 (HealthDay ... emotion in speech and other sounds, a finding that ... problems and impaired emotional perception. , "Quickly and ... translates across all arenas, whether in the predator-infested jungle ...
... CONSHOHOCKEN, Pa., March 13 Apollo Health Street has ... Payer segment in the prestigious Black Book of Outsourcing ... Apollo Health Street, states, "We appreciate the recognition from ... is an independent validation of our commitment to excellence.""The ...
... in the Schering-Plough Corporation Securities Litigation class action suit ... COURT, DISTRICT OF NEW JERSEY, ... MASTER FILE NO. 01-CV-0829 (KSH/MF), , ... SECURITIES DURING THE PERIOD FROM MAY 9, 2000 THROUGH ...
... Study shows giving up your keys has its down sideSAN ... The Journals of Gerontology (Medical Sciences) indicate that convincing older ... such a good idea.The study of 660 adults aged 63 ... to six times more likely to die over a three-year ...
Cached Medicine News:Health News:Transcept Pharmaceuticals to Report Fourth Quarter 2008 Results 2Health News:Transcept Pharmaceuticals to Report Fourth Quarter 2008 Results 3Health News:Musicians' Brains Tuned to Emotions in Sound 2Health News:Apollo Health Street Has Earned the Number One Spot in the Healthcare Payer Segment for BPO Services 2Health News:Settlement Hearing on Schering-Plough Corporation Securities Litigation to be Held on June 1, 2009 at 2:00 P.M. 2Health News:Settlement Hearing on Schering-Plough Corporation Securities Litigation to be Held on June 1, 2009 at 2:00 P.M. 3Health News:Settlement Hearing on Schering-Plough Corporation Securities Litigation to be Held on June 1, 2009 at 2:00 P.M. 4Health News:Drive or Die 2Health News:Drive or Die 3
... rate: 80 cc/minute. Pore ... filtering fluids at flow ... bi-directional membrane support rated ... psi) via prefilled syringe ...
4 mm x 4 mm downward biting jaws, curved right, length of shaft 115 mm, overall length 9.3 inches....
Straight, right side cutting, 1.5 mm x 4 mm bite, length of shaft 115 mm, overall length 6.3 inches....
Backward cutting, 3 mm x 7 mm bite, length of shaft 100 mm, overall length 7 inches....
Medicine Products: